A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection

Trial Profile

A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ION-4
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 16 Feb 2017 Results assessing correlation between urinary biomarkers and renal toxicity presented at the 24th Conference on Retroviruses and Opportunistic Infections.
    • 25 May 2016 Results of the retreatment substudy (n = 9) published in the Clinical Infectious Diseases.
    • 17 Apr 2016 Pooled analysis results from this trial and ION-4 trial with other 7 trial presented at The International Liver Congress™ 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top